Omnihealth Practice

MASLD drives persistent HCC risk despite HCV cure: Insights from a Japanese multicenter cohort study

A large multicenter cohort study revealed that metabolic dysfunction-associated steatotic liver disease (MASLD) remains a significant factor in the risk of hepatocellular carcinoma (HCC) even after chronic hepatitis C (HCV) has been eradicated with direct-acting antivirals (DAAs). These findings underscore the importance of post-cure risk stratification, long-term surveillance, and management of metabolic dysfunction to mitigate the residual burden of HCC.

NEPHROLOGY

30 Jan 2026

Parity and breastfeeding establish durable CD8⁺ T cell-mediated protection in TNBC

Triple-negative breast cancer (TNBC) is characterized by higher immune infiltration compared with other breast cancer subtypes.1 Parity and breastfeeding are established protective factors for breast cancer, particularly TNBC, reducing risk by approximately 7% per full-term birth and an additional 4

ONCOLOGY OBSTETRICS & GYNECOLOGY

16 Dec 2025

Baricitinib leads to significant scalp hair regrowth in adults and adolescents with severe AA: Results from the BRAVE-AA trials

STUDY DESIGN Baricitinib, a selective Janus kinase (JAK) inhibitor approved for severe alopecia areata (AA) in adults, has been evaluated in adolescents aged 12-18 years.1 Across both adult and adolescent studies, baricitinib demonstrated clinically meaningful hair regrowth, with ≥80% scalp coverag

DERMATOLOGY

30 Oct 2025

Lighting the path: How sentinel nodes guide EC care

In a recent expert discussion with Professor Nirmala Kampan, she shared her perspectives on the evolving role of this technique, from evidence-based outcomes to future innovation and directions in patient-centered care in EC.

OBSTETRICS & GYNECOLOGY ONCOLOGY

26 Nov 2025

Professor Dr. Nirmala Kampan

Consultant Obstetrician & Gynecologist,
Hospital Canselor Tuanku Muhriz UKM (HCTM-UKM),
Head of the Gyne-Oncology and Minimally Invasive Surgery Units,
Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM),
Kuala Lumpur, Malaysia

Guide to OSA in Hong Kong: Enhancing primary care response

In an interview with Dr. To, Wing-Hei Zion, he discussed the critical, yet often overlooked, issue of OSA within the local population. He highlighted that OSA is far more than a simple snoring problem; it is a systemic disease linked to a cascade of serious comorbidities, including hypertension, stroke, and diabetes. He provided a comprehensive overview for family medicine and GPs, covering practical screening methods, navigating local diagnostic pathways, and the latest patient-centered management, underscoring their vital role in improving long-term health outcomes by addressing this hidden epidemic.

20 Oct 2025

Dr. To, Wing-Hei Zion

Clinical Assistant Professor (Honorary),
Department of Otorhinolaryngology,
Head and Neck Surgery,
The Chinese University of Hong Kong

AASLD 2026

November 7-11 , 2025 | Washington, Unied States

MASLD drives persistent HCC risk despite HCV cure: Insights from a Japanese multicenter cohort study

NEPHROLOGY

30 Jan 2026

Multi-target blood test improves early detection of HCC: Evidence from the ALTUS prospective study

The prospective ALTUS study found that a multi-target HCC blood test (mt-HBT) outperformed ultrasound in detecting early- and very early-stage hepatocellular carcinoma (HCC). By providing operator-independent and scalable surveillance, mt-HBT offers a promising alternative to imaging, with the potential to enhance early detection, adherence, and clinical outcomes in at-risk patients.

NEPHROLOGY

04 Feb 2026

ESMO 2025

October 17-21 , 2025 | Berlin, Germany

Alectinib prolongs OS and shows durable response in previously untreated advanced ALK+ NSCLC: Final OS analysis from the phase 3 ALEX study

The ALEX study's final analysis shows that first-line alectinib significantly improves OS and duration of response in untreated advanced ALK+ NSCLC compared to crizotinib, reinforcing alectinib as the standard of care for these patients.

ONCOLOGY RESPIROLOGY

19 Nov 2025

Osimertinib + plat-pem shows consistent OS benefits in EGFRm advanced NSCLC irrespective of poor baseline prognostic factors: Exploratory OS analyses from FLAURA2

Findings from the FLAURA2 study reveal that combining osimertinib with platinum-pemetrexed significantly improves overall survival in patients with advanced EGFRm NSCLC, demonstrating clear benefits over monotherapy even in those with adverse baseline prognostic factors.

ONCOLOGY RESPIROLOGY

20 Nov 2025

Enhancing early lung cancer detection: Insights from HKU's lung nodule surveillance programme

Lung cancer remains one of the leading causes of cancer-related deaths in Hong Kong, with survival strongly linked to early-stage diagnosis. Despite advances in imaging, many lung cancers go undetected or are diagnosed late, limiting treatment options and outcomes.

ONCOLOGY

23 Nov 2025

CU Medicine and global experts develop Chinese-specific genetic risk score for T1D diagnosis

Accurate diagnosis of type 1 diabetes remains a major clinical challenge, with up to 40% of adults initially misclassified as having type 2 diabetes, leading to delayed insulin initiation and increased risk of complications. Most existing genetic risk scores were derived from European populations, with limited applicability in Asian populations due to differences in genomic architecture. This highlights the need for ancestry-specific tools. A study led by a joint research team from The Chinese University of Hong Kong (CUHK), the University of Exeter in the United Kingdom, and the Second Xiangya Hospital of Central South University in China developed and validated a Chinese-specific T1D genetic risk score that improves differentiation between T1D and T2D compared to European-derived models.

DIABETES & ENDOCRINOLOGY

29 Oct 2025

SC daratumumab approved in the EU as first treatment for high-risk SMM

Smoldering multiple myeloma (SMM) is an asymptomatic precursor of multiple myeloma, with high-risk patients facing a substantial likelihood of progression to symptomatic disease. Until now, there have been no approved treatment options for this patient population, and standard care has been limited to close monitoring. The recent European Commission (EC) approval of subcutaneous daratumumab, based on phase 3 AQUILA trial results, introduces the first licensed treatment for high-risk SMM and provides a new opportunity to delay or prevent progression to symptomatic disease.

HEMATOLOGY

16 Oct 2025

Raising the bar in AD care: Delivering deep and durable responses with lebrikizumab

Highlights Atopic dermatitis (AD) is driven by a cycle of barrier dysfunction and type 2 inflammation, with interleukin (IL)-13 playing a central role While traditional corticosteroids can control flares, they do not fully address the underlying immune-barrier interplay, l

DERMATOLOGY

09 Oct 2025

Professor Florian Lordick

Director, Comprehensive Cancer Center Central Germany (CCCG)
Director, Department of Medicine, University of Leipzig,
Germany

Ruxolitinib in high-risk PV: Addressing unmet needs and delivering durable clinical benefit

Polycythemia vera is a complex and chronic hematologic disorder. Despite established treatment protocols, many patients experience persistent symptoms and inadequate disease control, particularly when resistant or intolerant to first-line therapies.

HEMATOLOGY

12 Sep 2025

Professor Mary Frances McMullin

Professor of Hematology,
Queen’s University Belfast,
Northern Ireland

Every update. In your inbox.

Get access to our exclusive articles.

Extending endocrine care beyond β-thalassemia major: International consensus guideline in children and adolescents

Thalassemia arises from mutations in the α- or β-globin genes, with 5%-10% of the global population carrying α-thalassemia mutations and at least 40,000 children born with β-thalassemia annually. The disease is most prevalent in the Mediterranean, Middle East, Indian subcontinent, China, and Southeast Asia.

HEMATOLOGY PEDIATRICS

07 Nov 2025

Professor Dr. Muhammad Yazid Jalaludin

Senior Consultant Pediatric Endocrinologist,
Department of Pediatrics,
Universiti Malaya Medical Centre,
Kuala Lumpur, Malaysia

Empirical PPI therapy and subtype-based treatment show similar efficacy in FD

Functional dyspepsia (FD) is a common gut-brain interaction disorder that primarily affects adults and imposes a significant economic burden.¹ Treatment guidelines vary, leading to inconsistencies in management approaches.¹ A randomized, single-blinded trial was conducted to evaluate the efficacy of subtype-specific treatment vs. empirical proton pump inhibitor (PPI) therapy in adults with FD.¹ Findings suggest that both treatment approaches significantly improved the overall symptoms and health-related quality of life (HRQoL), with no clear advantage of either, over another in FD management.¹

GASTROENTEROLOGY & HEPATOLOGY

12 Jun 2025

Dr. Chuah, Kee-Huat

Associate Professor
Consultant Gastroenterologist & Hepatologist
Faculty of Medicine, University of Malaya,
Kuala Lumpur, Malaysia

Dual immunotherapy combination in pre-treated HCC: A case study in achieving 10-year remission

In an interview with Professor Yau, Chung-Cheung Thomas, he shared a case of 10-year survival in a patient with metastatic aHCC in the second-line setting managed with dual immune checkpoint inhibitors nivolumab + ipilimumab. Dr. Wong, Sum-Lung Jeffrey also provided insights into data from the CheckMate 040 trial and its Asian subgroup analysis, highlighting not only the efficacy and durability of the dual immune checkpoint inhibitors but also their manageable safety profile. The combination of nivolumab + ipilimumab marks a paradigm shift in HCC treatment, offering hope for long-term survival in a disease once considered universally fatal.

ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY

26 Jan 2026

Professor Yau, Chung-Cheung Thomas

Clinical Associate Professor,
Centre of Cancer Medicine/
Department of Medicine
School of Clinical Medicine,
LKS Faculty of Medicine,
The University of Hong Kong

Dr. Wong, Sum-Lung Jeffrey

Fellow in Medical Oncology

Case sharing: Tezepelumab targets upstream inflammation to bridge the divide in both severe T2-high and -low asthma

Asthma is a complex, chronic respiratory disease characterized by heterogeneous airway inflammation and variable clinical presentation.1 Within its spectrum, severe asthma represents a high-burden subgroup that contributes disproportionately to morbidity, healthcare utilization, and mortality.1,2 De

RESPIROLOGY IMMUNOLOGY & ALLERGY

19 Nov 2025

Professor Li, Hei Philip

Specialist in Immunology & Allergy,
Division Chief of Rheumatology & Clinical Immunology, Clinical Assistant Professor,
Department of Medicine,
The University of Hong Kong

Dr. Leung, Kei-Ching Gabriel

Enrichment Year MBBS student,
Li Ka Shing Faculty of Medicine,
The University of Hong Kong

CLDN18.2: A unique marker for gastric cancer in the precision oncology era

ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY

20 Nov 2025

Professor Matteo Fassan

Department of Pathology,
ULSS2 Marca Trevigiana
University of Padua,
Italy

Redefining AD management: Lecanemab introduces new formulation backed by 4 years of positive efficacy and safety data

NEUROLOGY

19 Nov 2025

Infographics

DERMATOLOGY

Better plate for clearer skin: Mediterranean diet reduces psoriasis burden

29 Jan 2026

HEMATOLOGY

Extending treatment with brentuximab vedotin to stage III classical Hodgkin lymphoma

23 Jan 2026

RHEUMATOLOGY

Decoding SSc-ILD in Hong Kong: Epidemiological Insights and Predictive Biomarkers

22 Sep 2025

OBSTETRICS & GYNECOLOGY ONCOLOGY DIABETES & ENDOCRINOLOGY CARDIOLOGY

Double jeopardy: Obesity + CVD linked to higher postmenopausal breast cancer risk

17 Sep 2025

NEUROLOGY

Dreams that steal time: Associating distressing dreams with early mortality

25 Jul 2025

IMMUNOLOGY & ALLERGY

CHOOSE THE RIGHT PROTECTION FOR YOU: A Guide to Subcutaneous (SC) or Intravenous (IV) Immunoglobulin (Ig)

25 Jul 2025

HEMATOLOGY ONCOLOGY

The Hidden Blueprint: CGAT Reveals Key Insights for Myelofibrosis Transplant

06 Apr 2025

DERMATOLOGY

Beneath The Surface Exploring Metabolic Syndrome in Chronic Spontaneous Urticaria

10 Feb 2025

OBSTETRICS & GYNECOLOGY PSYCHIATRY CARDIOLOGY

Heartfelt Connections: The Shadow of PND on Maternal CV Health

03 Dec 2024

OPHTHALMOLOGY NEPHROLOGY

Insight into CKD progression: Ophthalmalogical outcomes and eGFR in non-diabetic CKD

21 Jun 2024

CARDIOLOGY

CKD or No CKD: Knocking down CV risks with rosuvastatin

08 Jul 2024

NEUROLOGY

Longitudinal assessment of MCI and dementia in an essential tremor cohort

08 Jul 2024

HEMATOLOGY

From bridging to maintenance: A case of gilteritinib in RR FLT3 AML patients undergoing HSCT

09 May 2024

NEUROLOGY

Real-world effectiveness of fremanezumab in migraine prevention

08 Apr 2024

HEMATOLOGY CARDIOLOGY

Incidence of anemia with long-term low-dose aspirin

18 Mar 2024

Decoding the spectrum of tolerance in fish allergies

04 Jan 2024

DIABETES & ENDOCRINOLOGY CARDIOLOGY

Earlier and higher risk of CVD with a younger T2D diagnosis

04 Jan 2024

DIABETES & ENDOCRINOLOGY

U-shaped relationship between sleep duration and T2DM regardless of traditional lifestyle risk factors

17 Nov 2023

RESPIROLOGY

Brain Gliosis: A Potential Origin of Persistent Post-COVID-19 Depressive and Cognitive Symptoms

17 Nov 2023

DIABETES & ENDOCRINOLOGY NEUROLOGY

The nuanced link between prediabetes and dementia

23 Aug 2023

NEUROLOGY RHEUMATOLOGY

Connecting the dots between Parkinson’s disease and rheumatoid arthritis

12 Jul 2023

CARDIOLOGY PEDIATRICS

Cardio-oncology monitoring in pediatric populations - Delphi consensus recommendations from an Australian and New Zealand expert group

28 Apr 2023

RESPIROLOGY IMMUNOLOGY & ALLERGY

Targeting TSLP for severe asthma - Tezepelumab updates from the 2023 American Academy of Allergy Asthma & Immunology Annual Meeting

06 Apr 2023

HEMATOLOGY PEDIATRICS

A new way out for alpha thalassemia major - Give them a chance at life with In-utero transfusions

15 Mar 2023

RESPIROLOGY

Beware of overlapping phenotypes in severe asthma: The eosinophilia and IgE double whammy

27 Feb 2023

NEPHROLOGY

Stay on the path of treatment - Take on a high-K with ease
ASN abstract highlight on sodium zirconium cyclosilicate and hyperkalemia

23 Feb 2023

RESPIROLOGY

Real-world effectiveness of benralizumab around the globe

06 Dec 2022

RESPIROLOGY

Remission is within reach - Target the underlying drivers of inflammation with benralizumab

19 Sep 2022

ONCOLOGY RESPIROLOGY

PACIFIC-6: Durvalumab after CRT showed similar safety profile as the PACIFIC regimen with encouraging efficacy data in frailer and older patients with stage 3, unresectable NSCLC